CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
pazopanib hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01157091
NCT01157091Phase 2Completed
CompareCT.gov

A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC)

City of Hope Medical Center·interventional·Posted Jul 5, 2010·Updated Jun 8, 2022

In Brief

A Phase 2 clinical trial evaluating pazopanib hydrochloride, laboratory biomarker analysis, and 1 other intervention for Clear Cell Renal Cell Carcinoma and 2 related conditions. Completed, enrolled 28 participants across 2 sites.

Detailed Summary

RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients with stage IV kidney cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 5, 2010
Enrollment StartDec 8, 2010
Primary CompletionOct 17, 2013
Study CompletionDec 31, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.0 years ago

Interventions

pazopanib hydrochloridedrug

Given orally

laboratory biomarker analysisother

Correlative studies

immunologic techniqueother

Correlative studies